CJC-1295/Ipamorelin
A dual GH secretagogue blend studied for synergistic pituitary GH release through GHRH receptor and ghrelin receptor co-activation.
Overview
CJC-1295/Ipamorelin is a research blend combining two mechanistically distinct GH secretagogues. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog that binds to albumin via its maleimidoproprionic acid modification, extending its half-life to approximately 6 to 8 days and providing sustained GHRH receptor activation. Ipamorelin is a selective pentapeptide ghrelin receptor (GHS-R1a) agonist known for minimal cortisol and prolactin elevation relative to other GHS-R agonists. The combination produces synergistic GH secretion through complementary receptor pathways, and this dual-receptor approach has made the blend widely studied in body composition and GH axis research.
Quick Reference
- Components
- CJC-1295 (GHRH analog with DAC) + Ipamorelin (GHS-R1a agonist)
- CJC-1295 half-life
- Approx. 6 to 8 days (albumin-bound, with DAC)
- Ipamorelin selectivity
- GHS-R1a, minimal cortisol/prolactin effects
- Mechanism
- Dual-receptor GH secretagogue, cAMP and calcium channel synergy
- Purity standard
- >=98% by HPLC
How It Works
CJC-1295 activates the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and release through the cAMP/PKA pathway. Ipamorelin activates GHS-R1a (the ghrelin receptor) on the same cells through a complementary calcium channel pathway, and this dual stimulation produces greater GH secretion than either compound alone. The synergy between GHRH receptor and ghrelin receptor co-activation is a documented feature of combined secretagogue research.
Research Highlights
Key findings from the published preclinical literature.
Synergistic GH Release with Dual Receptor Activation
Research has documented that co-administration of GHRH analogs with GHS-R agonists produces greater GH secretion than additive effects from either compound alone, attributed to complementary intracellular signaling pathways (cAMP/PKA versus calcium channel) converging on somatotroph GH exocytosis.
Extended Half-Life of CJC-1295 via DAC Technology
The Drug Affinity Complex modification of CJC-1295 enables reversible covalent binding to serum albumin, extending half-life from approximately 30 minutes for unmodified GHRH to 6 to 8 days, enabling sustained receptor activation that distinguishes it from shorter-acting GHRH analogs.
Ipamorelin Selectivity for GHS-R1a
Comparative studies have documented that Ipamorelin produces GH secretion with substantially less cortisol and prolactin elevation than other GHS-R agonists including GHRP-6 and GHRP-2, attributed to its high selectivity for GHS-R1a without significant activity at other GHRP-sensitive receptors.
Body Composition Effects in Animal Models
Rodent studies examining sustained GH secretagogue treatment have documented effects on lean mass preservation, adipose tissue reduction, and IGF-1 elevation consistent with physiological GH axis stimulation, supporting the body composition research relevance of this compound class.
Research Connections
Related research areas, stacks, and comparisons involving this compound.
Research Stacks
Compound Comparisons
Frequently Asked Questions
Source This Compound
CJC-1295/Ipamorelin is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.